Last reviewed · How we verify

AskBio Inc — Portfolio Competitive Intelligence Brief

AskBio Inc pipeline: 0 marketed, 0 filed, 0 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Abeona Therapeutics, Inc · 1 shared drug class
  2. BioLab 612 LLC · 1 shared drug class
  3. Brain Neurotherapy Bio, Inc. · 1 shared drug class
  4. Emily de los Reyes · 1 shared drug class
  5. Eva Morava-Kozicz · 1 shared drug class
  6. Kolon TissueGene, Inc. · 1 shared drug class
  7. Krystal Biotech, Inc. · 1 shared drug class
  8. 4D Molecular Therapeutics · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for AskBio Inc:

Cite this brief

Drug Landscape (2026). AskBio Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/askbio-inc. Accessed 2026-05-13.

Related